OBJECTIVE-Obesity and associated pathologies are major global health problems. Transforming growth factor-b/Smad3 signaling has been implicated in various metabolic processes, including adipogenesis, insulin expression, and pancreatic b-cell function. However, the systemic effects of Smad3 deficiency on adiposity and insulin resistance in vivo remain elusive. This study investigated the effects of Smad3 deficiency on whole-body glucose and lipid homeostasis and its contribution to the development of obesity and type 2 diabetes.
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OBJECTIVE-Obesity and associated pathologies are major global health problems. Transforming growth factor-b/Smad3 signaling has been implicated in various metabolic processes, including adipogenesis, insulin expression, and pancreatic b-cell function. However, the systemic effects of Smad3 deficiency on adiposity and insulin resistance in vivo remain elusive. This study investigated the effects of Smad3 deficiency on whole-body glucose and lipid homeostasis and its contribution to the development of obesity and type 2 diabetes.
RESEARCH DESIGN AND METHODS-We compared various metabolic profiles of Smad3-knockout and wild-type mice. We also determined the mechanism by which Smad3 deficiency affects the expression of genes involved in adipogenesis and metabolism. Mice were then challenged with a high-fat diet to study the impact of Smad3 deficiency on the development of obesity and insulin resistance.
RESULTS-Smad3-knockout mice exhibited diminished adiposity with improved glucose tolerance and insulin sensitivity. Chromatin immunoprecipitation assay revealed that Smad3 deficiency increased CCAAT/enhancer-binding protein b-C/EBP homologous protein 10 interaction and exerted a differential regulation on proliferator-activated receptor b/d and proliferator-activated receptor g expression in adipocytes. Focused gene expression profiling revealed an altered expression of genes involved in adipogenesis, lipid accumulation, and fatty acid b-oxidation, indicative of altered adipose physiology. Despite reduced physical activity with no modification in food intake, these mutant mice were resistant to obesity and insulin resistance induced by a high-fat diet.
CONCLUSIONS-Smad3 is a multifaceted regulator in adipose physiology and the pathogenesis of obesity and type 2 diabetes, suggesting that Smad3 may be a potential target for the treatment of obesity and its associated disorders. Diabetes 60: [464] [465] [466] [467] [468] [469] [470] [471] [472] [473] [474] [475] [476] 2011 O besity is a global medical issue by virtue of its association with an array of metabolic abnormalities, including insulin resistance, hypertension, and hyperlipidemia, collectively termed "metabolic syndrome" (1) . Thus, the need is urgent for elucidation of the molecular events underlying the development of metabolic syndrome and for identification of novel targets for disease prevention and therapy.
Obesity is primarily characterized by increased fat mass or white adipose tissue (WAT). WAT consists of adipocytes specialized in the storage of fat (2) . In addition to its primary function as an energy reservoir, WAT is an endocrine organ that secretes adipocytokines (e.g., leptin and resistin) that have been shown to regulate glucose and lipid metabolism (3) . In obesity, adipose secretion of adipocytokines is disturbed. The mechanisms that underlie obesity-associated pathologies, such as insulin resistance, are likely to involve communication among different organs, such as insulin-responsive skeletal muscle and WAT (4, 5) . It has been proposed that adipose lipid storage functions to prevent peripheral lipotoxicity (5) . The excessive lipid accumulation in skeletal muscle and liver leads to insulin resistance resulting from the adverse effects of chronic lipotoxicity on these tissues (5, 6) . Indeed, free fatty acids (FFAs) can inhibit insulin activation of insulin receptor substrate-1-associated phosphatidylinositol-3-kinase activity in skeletal muscle (7) .
Studies have shown that the three peroxisome proliferatoractivated receptor isotypes (PPARa, b/d, and g) play central roles in this process (8) (9) (10) . PPARa activation decreases dyslipidemia and regulates obesity in rodents by both increasing hepatic FFA oxidation and decreasing levels of circulating triglycerides responsible for adipocyte hypertrophy and hyperplasia (11, 12) . The transcriptional upregulation of PPARg during adipogenesis is well studied. Adipogenic hormones, such as glucocorticoids, cyclic AMP, and insulin, induce a transient increase in the expression of the transcription factors CCAAT/enhancerbinding protein (C/EBP) b and d early in adipocyte differentiation. Together they induce PPARg expression in preadipocytes, subsequently triggering full-blown adipocyte differentiation (13) . PPARb/d plays important functions in adipose tissue metabolism, weight control, and regulation of insulin sensitivity (14) . PPARb/d protects against weight gain, hypertriglyceridemia, and insulin resistance in mice fed a high-fat diet (HFD) and in animals that are genetically predisposed to obesity (15) . Thus, available information suggests that obesity and other facets of metabolic syndrome involve deregulation of signaling pathways mediated by PPAR.
Transforming growth factor (TGF)-b1 signals through a complex of two membrane-bound receptor serine/threonine kinases that recruit and phosphorylate Smad2 and Smad3. Once phosphorylated, Smad2 and Smad3 oligomerize with Smad4 and translocate to the nucleus to participate in transcriptional regulation (16) . TGF-b1 has been reported to inhibit adipogenesis, although these findings were derived from in vitro preadipocyte models (17, 18) . Smad3 was shown to bind C/EBP and repress its transactivation potential, thus abolishing the expression of PPARg2 (17) . However, the in vivo effect of Smad3 on adiposity remains unclear. Elevated expression and plasma levels of TGF-b1 have been reported in WAT from obese mice and in diabetic patients, respectively (19, 20) . TGFb1/Smad3 was also shown to regulate insulin gene expression and pancreatic b-cell function (21) . Conceivably, this will have an impact on energy homeostasis. However, the effects of Smad3 on communications among insulin-responsive organs toward the development of diet-induced obesity and type 2 diabetes have not been examined in vivo.
We show that Smad3-knockout (KO) mice have reduced adiposity associated with impaired lipid accumulation and adipogenesis. We revealed that this distinct phenotype might be associated with altered expression of PPARg2 and b/d in the adipose tissue. Despite their reduced physical activity arising from muscle atrophy, these KO mice are resistant to HFD-induced obesity. The deficiency of Smad3 also confers improved glucose tolerance and insulin sensitivity.
RESEARCH DESIGN AND METHODS
Animals. Smad3 heterozygous mice on a C57BL/6 J background were intercrossed to produce Smad3-KO and wild-type (WT) offspring (22) . Male mice of the same age were used in all experiments. Hyperinsulinemic-euglycemic clamp studies. Clamp studies were performed as previously described (23) . In vitro insulin-induced glucose uptake assay. After fasting (15 h), tissues were harvested, followed by incubation in a Krebs-Ringer bicarbonate buffer. (25) . Lipolysis in adipocytes. Lipolysis was determined from freshly isolated adipocytes by measurement of glycerol released into the medium as previously described (27) . Lipid extraction from peripheral organs. Lipid was extracted from tissues by a Folch extraction as previously described (28, 29) . Statistical analysis. Statistical analysis was performed using two-tailed Mann-Whitney tests. Values were expressed as mean 6 SEM. P , 0.05 was considered statistically significant. Detailed description of various methods can be obtained from the corresponding author.
RESULTS
Smad3-KO mice exhibit reduced adiposity, hypoglycemia, and hyperinsulinemia. Eight-week-old Smad3-KO mice were characterized by reduced weight and short body length when compared with WT mice (Fig.  1A and B) . To identify the cause of these anomalies in KO mice, we measured the weight of several organs, expressed as percent body weight. The weights of the liver, muscle, and brown adipose tissue were similar in WT and KO mice ( Supplementary Fig. 1A-C) . WAT weight from various fat pad depots was reduced by ;63% in KO mice ( Fig. 1C-E) . Total body composition analysis by quantitative nuclear magnetic resonance further confirmed that fat content in KO mice was reduced by ;63% (WT = 11.36 6 1.51% vs. KO = 4.18 6 0.29%; P , 0.05), whereas as expected from this observation, the proportion of the lean mass was consistently higher in KO mice (WT = 72.29 6 1.24% vs. KO = 80.01 6 0.49%; P , 0.01) (Fig. 1F ). Smad3-KO epididymal WAT contained smaller adipocytes than their WT counterparts (WT = 2,206.03 6 153.08 mm 2 vs. KO = 567.49 6 34.11 mm 2 ; P , 0.001) ( Fig. 1G and H) . Fluorescence-activated cell sorting analysis comparing KO and WT WAT using Nile Red staining revealed a smaller and reduced number of adipocytes in KO mice ( Fig. 1I and  J) . No significant difference in cell proliferation in WAT and liver histology was observed for both genotypes (Supplementary Fig. 1D and E). Smad3-KO mice show increased peripheral insulin sensitivity. To uncover the systemic manifestations of reduced adiposity, we measured plasma lipid and glucose parameters in WT and KO mice. Although the plasma triglyceride level was elevated in KO mice, the FFA and glycerol levels were reduced, suggesting decreased lipolysis ( Fig. 2A-C) . Plasma cholesterol levels remained unchanged ( Supplementary Fig. 1F ). KO mice displayed hyperinsulinemia and were hypoglycemic regardless of feeding status ( Fig. 2D and E). KO mice exhibited significantly faster reduction in blood glucose concentration after glucose administration (Fig. 2F ), and they were more sensitive to insulin, as indicated by the prolongation of blood glucose-lowering effects of insulin in these animals ( Fig. 2G ).
These findings suggested that Smad3 deficiency improved glucose tolerance and insulin responsiveness. To understand the mechanisms of improved insulin sensitivity in KO mice, the protein expression levels of key mediators of insulin-signaling cascades were examined. Immunoblot analysis of WAT and skeletal muscle revealed increased GLUT4, insulin receptor substrate-1, phosphorylated FoxO1, GSK-3b, Akt, and ERK expression in Smad3-KO mice when compared with WT mice (Fig. 2H) . Next, we measured in vivo insulin-stimulated glucose uptake by using hyperinsulinemic-euglycemic clamp studies. During constant hyperinsulinemia, a higher glucose infusion rate was required to maintain normal glucose levels in KO mice compared with WT mice (Fig. 2I and J) . To determine the insulin-stimulated glucose uptake of skeletal muscle and WAT, we assessed 2-deoxy-D- [1,2- 3 H]glucose (2-DG) uptake during clamp studies. Whole-body glucose utilization (peripheral insulin sensitivity) and percentage of insulinmediated suppression of hepatic glucose production (hepatic insulin sensitivity) were significantly increased in the KO mice ( Fig. 2K and L) . We also found a significant increase of 2-DG uptake into the soleus, gastrocnemius muscles, and WAT of KO mice (Fig. 2M ). Data from in vitro 2-DG uptake of isolated soleus muscle and WAT were congruent with the in vivo findings that KO mice are more insulin-sensitive than WT ( Fig. 2N and O). Smad3-KO mice display decreased physical activity. Next, we explored the impact of Smad3 deletion on wholebody metabolic activity in the absence of a dietary challenge. To this end, mice were fed a standard chow diet, and various metabolic parameters were monitored using metabolic cages. We observed no significant differences in food and water consumption ( Fig. 3A and B) , O 2 consumption (Fig. 3C ), CO 2 production (Fig. 3D) , and metabolic rate (heat production) (Fig. 3E ) between WT and KO mice (Supplementary Fig. 2A-D) . Both genotypes consumed carbohydrates as the main energy source given that their respiratory exchange ratio (RER), which equals VO 2 /VCO 2 , was .0.92 (Fig. 3F ). The RER indicates whether carbohydrates (RER = 1.0) or lipids (RER = 0.7) are being used to produce energy.
KO mice exhibited a decrease of ;74% in both horizontal and rearing movements ( Fig. 3G and H, Supplementary  Fig. 2E and F). Macroscopic comparison between WT and KO showed a ;10% reduction in muscle fiber size ( Fig. 3I and J). Real-time qPCR analysis comparing WT and KO muscle revealed no difference in the expression of genes involved in b-oxidation or lipolysis (Fig. 3K) .
The liver may contribute to the reduced adiposity in KO mice via increased fatty acid (FA) b-oxidation. qPCR analysis revealed no difference in mRNA expression level of some genes involved in b-oxidation between WT and KO liver ( Supplementary Fig. 3A ). In vitro total b-oxidation assay also showed no significant difference in the oxidation of [ 14 C]palmitate in KO and WT hepatocytes ( Supplementary Fig. 3B ). These results indicate that the reduced adiposity in KO mice did not stem from increased energy expenditure arising from physical activity or increased hepatic b-oxidation. Smad3-KO mice show increased b-oxidation and impaired lipolysis in WAT. Two factors contribute to the expansion of WAT mass: increased size of existing adipocytes because of fat accumulation and the formation of new adipocytes through adipogenesis. Fat mass reflects the ratio between lipogenesis and lipolysis/b-oxidation. To examine the role of Smad3 in adipocyte physiology, we performed focused qPCR array on WT and KO WAT. The expression of several antiadipogenic factors, such as preadipocyte factor 1 (Pref-1), cyclin D1, and C/EBP homologous protein 10 (CHOP-10), was elevated by twofold or more in KO adipocytes, whereas there was a reduced PPARg2 expression, suggesting that Smad3 deficiency inhibits adipogenesis (Fig. 4A) . PPARg2-regulated genes, such as PEPCK and fatty acid synthase (FAS), were also downregulated (Fig. 4A) . The expression of the SREBP-1c, which stimulates many genes involved in FA metabolism and potentiates the transcriptional activity of PPARg2, was decreased in KO mice. Furthermore, the expression of elevated in the KO WAT, suggesting an increase FA boxidation and thermogenesis (Fig. 4A) . The protein levels of selected genes were similarly altered (Fig. 4B) .
To strengthen the observations, we determined the effect of Smad3 deficiency on triglyceride metabolism. We measured [ 14 C]palmitate uptake and its conversion into triglycerides in WT and KO adipocytes. We observed a 1.7-fold increase in [ 14 C]palmitate uptake in KO adipocytes compared with WT (102.5 6 9.4 nmol/10 5 cells vs. 61.0 6 8.8 nmol/10 5 cells, respectively; Fig. 4C) . Notably, the increased FA uptake was not accompanied by a concomitant increased conversion into triglycerides, which were reduced in KO adipocytes when compared with WT (0.26 6 0.11 nmol/10 5 cells vs. 0.49 6 0.17 nmol/10 5 cells, respectively; Fig. 4D ). We also assayed the levels of glycerol released into the culture medium as an indicator of lipolysis. Smad3 deficiency led to a twofold decrease in glycerol release (WT = 2. (30) . To gain insight into the regulation of PPARb/d in adipocytes, we performed in vivo coimmunoprecipitation and chromatin immunoprecipitation (ChIP) using anti-C/EBPb antibodies in WT and KO mice (Fig. 5A ). ChIP and re-ChIP assays showed that in the WT WAT, C/EBPb was associated with a specific C/EBP binding site at 494-485 bp upstream from the PPARb/d promoter. The data further showed that the association results in recruitment to this element of a transcriptional repressor complex containing histone deacetylase 1 (HDAC1) (Fig.  5B) , indicating a C/EBPb-mediated repression of PPARb/d. Notably, the association of C/EBPb-HDAC1 complexes with this binding site was reduced in KO WAT (Fig. 5B) . This association was further confirmed by qPCR normalized to chromatin before immunoprecipitation (i.e., input) (Fig.  5C) . No amplification was observed using preimmune IgG or a control DNA sequence (21179 to 2894).
Smad3 deficiency resulted in elevated expression of CHOP-10 (Fig. 4B) . We examined possible involvement of CHOP-10 in the ability of C/EBPb to regulate PPARb/d transcription. In vivo co-immunoprecipitation with anti-C/ EBPb followed by immunoblot with anti-CHOP-10 ( Fig.  5A ) revealed that the interactions between C/EBPb and CHOP-10 are markedly enhanced in KO WAT (Fig. 5D) . Thus, increased C/EBPb-CHOP-10 interactions removed the inhibitory effect of C/EBPb on PPARb/d promoter, resulting in increased PPARb/d expression in KO mice (Fig. 5E) .
C/EBPb is closely involved in the regulation of PPARg in adipocytes (31) . As expected, ChIP assay involving the PPARg2 promoter showed that C/EBPb was bound to the C/EBP binding site. In contrast with the PPARb/d promoter results, no amplification was detected after re-ChIP with anti-HDAC1 (Fig. 5B) . In KO WAT, only weak amplification resulted with anti-C/EBPb (Fig. 5B) . The increased C/EBPb-CHOP-10 interactions in the KO when compared with WT adipocytes (Fig. 5D ) also diminished PPARg2 promoter activity (Fig. 5B ). These observations show that Smad3 deficiency alters adipose physiology, causing a change associated with diminished PPARg2 and increased PPARb/d expression (Fig. 5E ). Smad3-KO mice are resistant to HFD-induced obesity and insulin resistance. A chronic HFD treatment induces obesity and obesity-associated insulin resistance in mice (32) . To examine the effect of Smad3 deficiency on HFDinduced obesity and insulin resistance, we placed KO and WT mice on a low-fat diet (LFD) or HFD for 18 weeks. On an HFD, WT mice became obese and were significantly heavier than those on an LFD (Fig. 6A and B) . In contrast, no significant difference in body weight gain was observed in KO mice on either diet, indicative of their resistance to HFD-induced obesity (Fig. 6A and B) . There was no difference in the mean daily food intake per mouse, regardless of diet, throughout the study ( Supplementary Fig. 4A and B).
As expected, HFD induced an increase in adipose mass in all fat depots in WT mice ( Fig. 6C and D) . This increase of 33% in WAT was associated with hypertrophy of adipocytes ( Fig. 6E and F) when compared with LFD controls. No significant difference in adipocyte size was observed between KO mice on either diet (Fig. 6E and F) . Histologic analysis of the liver from WT mice on an HFD showed macrovesicular hepatic steatosis as evidenced by a fatty liver populated with abundant large vacuolar lipid droplets (Fig. 6G) . We also observed small lipid droplets in the liver of WT mice on an LFD. Notably, the liver of KO mice had few or no lipid droplets and did not develop hepatic steatosis, regardless of treatment (Fig. 6G) . HFD induced an increase in triglyceride level in liver, skeletal muscle, and pancreas of WT mice when compared with LFD controls. No significant difference in tissue triglyceride level was observed between KO mice on either diet (Fig. 6H-J, Supplementary Fig. 4C and D) . KO mice exhibited a higher plasma triglyceride level compared with WT mice on an LFD (Fig. 7A) . As expected, the plasma triglyceride level was increased in WT and KO mice on an HFD, with the former reaching a level comparable to that of the KO mice under an LFD (Fig. 7A) . The levels of glycerol and FFA were significantly elevated in WT and KO mice on an HFD (Fig. 7B and C) , but remained lower in KO mice on either diet. Similarly, regardless of the diet and feeding status, KO mice consistently showed lower blood glucose levels (Fig. 7D) . No significant difference in plasma cholesterol level was detected ( Supplementary  Fig. 4E ). In agreement with these results, KO mice exhibited higher insulin levels under an LFD, but in contrast with WT mice, HFD treatment did not significantly increase these levels (Fig. 7E) .
Glucose tolerance and insulin sensitivity tests (ISTs) were carried out to determine the effects of an HFD on the WT and KO mice. The blood glucose of WT mice on an HFD only started to decrease at 45 min after glucose administration and failed to return to the basal level even at the 120-min time point, indicative of impaired glucose tolerance in these diet-induced obese mice. By contrast, KO mice under an HFD retained the rapid glucose clearance ability as previously observed under the standard diet (Fig.  7F) . In addition, HFD-induced obese WT mice also clearly displayed obesity-associated insulin resistance (Fig. 7G) , which was absent in KO mice. In vivo insulin-stimulated glucose uptake by using hyperinsulinemic-euglycemic clamp studies (Fig. 7H-J ) and in vitro tissue-specific insulinstimulated 2-DG uptake (Fig. 7K and L) indicated that KO mice were more tolerant to HFD-induced peripheral insulin resistance compared with WT mice. In concordance, the protein expression levels of indicated key mediators of insulin-signaling cascades were elevated in the WAT and skeletal muscle of HFD-fed KO mice (Fig. 7M) . Altogether, these observations indicated that KO mice are resistant to HFD-induced obesity and numerous obesity-linked pathologies.
DISCUSSION
Obesity increases risk for type 2 diabetes, hypertension, and cardiovascular diseases. Accordingly, much research effort currently targets identification of molecular targets and the development of drugs that reduce fat mass and improve insulin sensitivity. We examined the effect of Smad3 deficiency on adiposity in mice. By using Smad3-KO mice, we showed that Smad3 deficiency resulted in decreased adiposity associated with improved glucose tolerance and insulin responsiveness. Despite decreased physical activity, Smad3-KO mice were resistant to HFDinduced obesity. The deficiency in Smad3 also conferred resistance to the development of obesity-associated glucose intolerance, insulin resistance, and liver steatosis, thus providing an insight into the role of Smad3 in the pathogenesis of obesity and type 2 diabetes. Previous in vitro studies showed that Smad3 inhibits the transactivation potential of C/EBPs and consequently abolishes the stimulation of the adipogenic master regulator PPARg2 (17) . In fact, an increase in adiposity might be anticipated in the absence of the inhibitory effect of Smad3 on C/EBPs, as in the case of Smad3 deficiency. We found that Smad3-KO mice displayed decreased adiposity resulting from reduced adipocyte number and size, suggesting defective adipogenesis and altered lipid accumulation. Gene expression profiling of the Smad3-KO WAT revealed reduced expression of PPARg2 mRNA, with increased expression of the preadipocyte-specific marker Pref-1. PPARg2 not only participates in adipogenesis and survival but also promotes lipid storage (33) . Lipid accumulation relies on lipogenesis, which involves de novo synthesis of FA and glycerol, FA uptake, and synthesis of triglycerides. Notably, the expression of rate-limiting enzymes involved in these processes, such as FAS, PEPCK, and diacylglycerol acyltransferase, was downregulated in the Smad3-KO WAT (34) . The reduced lipogenesis is exacerbated by concomitant downregulation of enzymes participating in the pentose phosphate pathway required for de novo synthesis of biomolecules. Lending support, knockout or adipose-specific deletion of some examined genes in mice has resulted in similar phenotypic features in Smad3-KO mice. Pref-1-null mice, for instance, display obesity and increased serum lipid metabolites (35) . Adipose-specific knockout of PEPCK results in a fraction of mice developing lipodystrophy (36) . As a central enzyme in lipogenesis, FAS has been identified as a candidate gene for determining body fat (37) . Smad3 deficiency also resulted in increased FA b-oxidation as evidenced by the reduced plasma FFA level, offering another plausible explanation for the reduced adipocyte size in the Smad3-KO mice. Altogether, these findings indicate that Smad3 deficiency leads to impaired adipogenesis and lipogenesis in mice.
It has been proposed that adipose lipid storage functions to prevent peripheral lipotoxicity (5) . Particularly evident in HFD-induced obesity, the chronic accumulation of FFA in skeletal muscles and liver eventually dampens their insulin responsiveness (5, 7) . Indeed, the ablation of PPARg2 in obese mouse models results in reduced fat mass but leads to severe insulin resistance, b-cell failure, and dyslipidemia because of deposition of toxic reactive lipid species in the peripheral organs (38) . However, this reported insulin resistance and b-cell failure were not observed in the Smad3-KO mice, which also exhibited reduced expression of adipose PPARg2. This outcome may partly be the result of elevated plasma insulin levels and insulin hypersensitivity, which caused hypoglycemia in these mice. Indeed, our results also revealed enhanced insulin responsiveness in peripheral organs, such as skeletal muscle and WAT. Insulin activation of phosphatidylinositol-3-kinase/protein kinase B (PKB) (Akt) can inhibit TGF-b1 signaling via the formation of a PKB-Smad3 complex. This interaction does not inhibit PKB activity, but inhibits Smad3-mediated gene regulation (39, 40) . A recent study showed that Smad3 occupies the insulin gene promoter to repress its expression and increases glucose-stimulated insulin secretion because of enhanced insulin signaling in b-cell islets (21) . Furthermore, the expression of adipocytokines, such as visfatin and resistin, can influence glucose uptake and metabolism (41) . An increase in glucose uptake and glycolysis with the effects of these adipocytokines and a decreased plasma FFA level as observed in the Smad3-KO mice may partially contribute to the improved glucose tolerance and enhanced insulin sensitivity in these animals. Altogether, these findings place Smad3-PKB at a point of convergence in the crosstalk between TGF-b/Smad3 and insulin signaling pathways and provide insights into their roles in the development of obesity and insulin resistance. Our findings that Smad3-KO mice displayed increased insulin-stimulated whole-body (peripheral insulin sensitivity) and tissue-specific (skeletal muscle and WAT) glucose uptake underscored the relevance of this crosstalk in vivo.
The skeletal muscle is the largest energy consumer in mice and plays an important role in lowering plasma FFA and glycerol (42, 43) ; however, we found that Smad3-KO mice exhibited reduced physical activity associated with muscular atrophy, in concordance with a role of Smad3 in b 2 -adrenergic-induced muscle hypertrophy (44) . Thus, it is unlikely that increased energy expenditure in the skeletal muscles could account for the reduced adiposity in these mice. Although adipose tissue is not a major energy consumer compared with the skeletal muscle, increased b-oxidation in WAT can have a profound impact on adiposity and insulin sensitivity (41) . Comparative gene expression analysis of WT and Smad3-KO WAT revealed upregulation of PPARb/d, UCP2, UCP3, and acyl-CoA oxidase 1, all of which are involved in energy dissipation and peroxisomal FA oxidation. The activation of PPARb/d in obese mice has been shown to selectively induce expression of an array of genes required for adipose FA catabolism and thermogenesis but not genes involved in lipogenesis and fat storage, which are controlled by PPARg2 (14) . Metabolic rate remained unchanged in Smad3-KO mice, reflecting a balance between reduced skeletal muscle activity and increased adipose lipid oxidation. Many regulatory mechanisms may influence the expression of PPARg and PPARb/d in adipocytes. The relative proportion of homodimeric or heterodimeric C/EBP is likely to play important role. Although concentration at the indicated time points after IST. OGTT and IST were performed on mice fasted for 6 h on an 18-week LFD or HFD regimen. Data represent mean 6 SEM, n = 10/group. H-J: Hyperinsulinemic-euglycemic clamp studies of Smad3-KO and WT mice. Glucose infusion rate required to maintained euglycemia in KO and WT mice (H); whole-body glucose uptake (peripheral insulin sensitivity) (I); 2-DG uptake by soleus, gastrocnemius muscles, and WAT of HFD-fed KO and WT mice during clamp studies (J). Data are represented as mean 6 SEM, n = 5/group. K-L: In vitro insulin-stimulated glucose uptake in skeletal muscles and WAT. 2-DG uptake into soleus muscle (K) and WAT (L) was measured for 30 min. it is essential for PPARg2 expression, C/EBPb inhibits PPARb/d promoter activity. CHOP-10, which exhibited elevated expression in Smad3-KO WAT, acts as a dominantnegative inhibitor of C/EBP by preventing its binding to DNA (45) ; this function adds to the complexity of regulating the expression of these two PPAR isotypes with apparent opposing functions in the adipocyte. The reason for the differential regulation is unclear but may be attributed to different promoter context. The functional AP-1 site driving induction of the PPARb/d promoter is in close proximity to the identified C/EBP binding region. Smad3 may interact with c-JUN (AP-1), inhibiting c-JUN activity that is necessary for AP-1-stimulated PPARb/d expression, as reported in keratinocytes (46) .
In summary, we have found that Smad3 is a multifaceted regulator in glucose and lipid metabolism, as well as in the pathogenesis of obesity and type 2 diabetes, thus identifying Smad3 as a potential target for the treatment of obesity and its associated disorders.
